西维斯健康公司宣布,符合条件的联邦医疗保险(Medicare)受益人将能够以每月50美元的价格获取GLP-1类药物,此项安排将持续至2027年12月31日。这一举措旨在提升患者对这类重要药物的可及性。GLP-1药物通常用于治疗2型糖尿病和肥胖症,其市场需求持续增长。通过设定可负担的月度费用,西维斯健康致力于减轻符合资格受益人的经济负担,并支持其长期健康管理。该计划预计将持续数年,为众多参保者提供稳定的药物成本保障。
西维斯健康公司宣布,符合条件的联邦医疗保险(Medicare)受益人将能够以每月50美元的价格获取GLP-1类药物,此项安排将持续至2027年12月31日。这一举措旨在提升患者对这类重要药物的可及性。GLP-1药物通常用于治疗2型糖尿病和肥胖症,其市场需求持续增长。通过设定可负担的月度费用,西维斯健康致力于减轻符合资格受益人的经济负担,并支持其长期健康管理。该计划预计将持续数年,为众多参保者提供稳定的药物成本保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.